The major restructure is expected to deliver $550 million in savings over 3 years.
CSL signage at the main entrance of it's offices and manufacturing plant in Parkville in Melbourne, Australia on Nov. 6, 2020. Asanka Ratnayake/Getty Images
Australian biotech giant CSL has announced a sweeping restructure that will see around 4,800 jobs cut, equal to 15 percent of its workforce, as part of efforts to streamline operations.
The company will also shut 22 underperforming plasma centres in the 2026 financial year.
Naziya Alvi Rahman
Author
Naziya Alvi Rahman is a Canberra-based journalist who covers political issues in Australia. She can be reached at [email protected].
